ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025
[Research Progress of TNMB Staging in Lung Cancer].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the malignant tumor with the highest incidence and mortality in China, and accurate clinical staging is crucial for judging its prognosis and formulating treatment strategies. Currently, the internationally recognized tumor-nodule-metastasis (TNM) staging system centers on tumor anatomical characteristics but struggles to reflect the biological essence of tumors. Based on the TNM staging, the TNM-blood (TNMB) staging incorporates blood molecular biomarkers to achieve multi-dimensional assessment of anatomical and biological characteristics. Initially applied to cutaneous T-cell lymphoma, it has gradually expanded to the field of lung cancer in recent years. This review summarizes the existing research and applications of TNMB staging in lung cancer, comparatively analyzes the differences between TNMB and the traditional TNM staging in terms of staging basis, evaluation dimensions and clinical efficacy, and further summarizes the existing types of molecular biomarkers related to B staging as well as those expected to be included in B staging. .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.